Press releases
- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
- Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
- Precigen Reports First Quarter 2024 Financial Results and Business Updates
- Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- Actym Therapeutics Appoints Thomas Smart as CEO
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
- Precigen Reports Full Year 2023 Financial Results and Business Updates
More ▼
Key statistics
On Friday, Precigen Inc (I5X:DUS) closed at 1.50, -9.52% below its 52-week high of 1.66, set on Sep 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.56 |
---|---|
High | 1.56 |
Low | 1.50 |
Bid | 1.51 |
Offer | 1.56 |
Previous close | 1.53 |
Average volume | 1.88k |
---|---|
Shares outstanding | 252.42m |
Free float | 223.44m |
P/E (TTM) | -- |
Market cap | 411.44m USD |
EPS (TTM) | -0.3896 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 18:31 BST.
More ▼